• Medicine
  • Published 2005

Effect of AMD3100 on T Lymphocyte Subpopulations in Apheresis Products of Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation for Non Hodgkin Lymphoma.

@inproceedings{Holtan2005EffectOA,
  title={Effect of AMD3100 on T Lymphocyte Subpopulations in Apheresis Products of Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation for Non Hodgkin Lymphoma.},
  author={Shernan Grace Holtan and Luis F Porrata and David J. Inwards and Stephen A. Ansell and Douglas J. Padley and Ivana N. Micallef and Mark R Litzow and Patrick B. Johnston and Suzanne R. Hayman and S Kumar and Morie A Gertz and Martha Q Lacy and Angela Dispenzieri and Dennis A. Gastineau and Ayalew Teferi and Michelle A. Elliot and William J Hogan and Svetomir Nenad Markovic},
  year={2005}
}
AMD3100, a CXCR4 receptor antagonist, has been studied as a stem cell mobilization agent for the purpose of autologous stem cell transplantation (ASCT) in hematologic malignancies. Lymphocyte subset analysis of peripheral blood in patients treated with AMD3100 has been studied in healthy volunteers. To date, no reports exist describing the lymphocyte subsets of the autograft in patients undergoing AMD3100 stem cell mobilization for the purposes of ASCT in non-Hodgkin lymphoma (NHL). Considering… CONTINUE READING

Citations

Publications citing this paper.